J. Sanz

L. Fañanás, S. Papiol, V. Molina, 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry

V. Molina, J. Sanz, J. A. Hernández, 2010, Psychiatry Research: Neuroimaging.

Dorsolateral prefrontal N-acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder

M. Desco, V. Molina, J. Sanz, 2007, European Psychiatry.

Marked Hypofrontality in Clozapine-responsive Patients

V. Molina, J. Sanz, F. Sarramea, 2007, Pharmacopsychiatry.

Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia

V. Molina, J. Sanz, C. Benito, 2004, International clinical psychopharmacology.

Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin‐1 beta gene (2q13)

L. Fañanás, M. Desco, S. Papiol, 2008, Genes, brain, and behavior.

Dorsolateral prefrontal and superior temporal volume deficits in first–episode psychoses that evolve into schizophrenia

V. Molina, J. Sanz, F. Sarramea, 2006, European Archives of Psychiatry and Clinical Neuroscience.

Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.

A. Lahti, C. Arango, J. Sanz, 2006, The American journal of psychiatry.

Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia

M. Desco, J. Pascau, V. Molina, 2002, Neurotoxicity Research.

Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients

Vicente Molina, Carlos Benito, Tomás Palomo, 2004, Psychiatry Research: Neuroimaging.

Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia

Manuel Desco, Javier Pascau, Vicente Molina, 2003, Psychiatry Research: Neuroimaging.

Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia

Manuel Desco, Javier Pascau, Vicente Molina, 2003, Psychiatry Research: Neuroimaging.

Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia

Manuel Desco, Javier Pascau, Vicente Molina, 2002, Schizophrenia Research.

Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients

Vicente Molina, Javier Sanz, Sergi Papiol, 2011, NeuroImage.

Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia

Vicente Molina, Tomás Palomo, V. Molina, 2009, Psychiatry Research: Neuroimaging.

Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis.

G. Rubio, J. Sanz, T. Palomo, 2012, Comprehensive psychiatry.

N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration

Manuel Desco, Javier Pascau, Vicente Molina, 2005, Schizophrenia Research.

Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia

Manuel Desco, Javier Pascau, Vicente Molina, 2005, Schizophrenia Research.

Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity.

Vicente Molina, Carlos Benito, Tomás Palomo, 2005, Journal of psychiatric research.

Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene

Manuel Desco, Vicente Molina, Santiago Reig, 2005, NeuroImage.

Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement

Andrés Santos, Manuel Desco, Javier Pascau, 2005, Psychopharmacology.

Changes in Cortical Volume with Olanzapine in Chronic Schizophrenia

M. Desco, J. Pascau, V. Molina, 2007, Pharmacopsychiatry.

Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia

M. Desco, J. Pascau, V. Molina, 2005, International clinical psychopharmacology.

Cerebral metabolism and risperidone treatment in schizophrenia

M. Desco, A. Santos, J. Pascau, 2003, Schizophrenia Research.

Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry

V. Molina, J. Sanz, J. A. Hernández, 2010, Psychiatry Research: Neuroimaging.

Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients

V. Molina, J. Sanz, F. Sarramea, 2004, Psychiatry Research: Neuroimaging.

Cerebral metabolic patterns in chronic and recent-onset schizophrenia

Andrés Santos, Manuel Desco, Javier Pascau, 2003, Psychiatry Research: Neuroimaging.

Hypofrontality in men with first-episode psychosis

M. Desco, J. Pascau, J. Pascau, 2005, British Journal of Psychiatry.

Hypofrontality in men with first-episode psychosis Hypofrontality in men with first-episode psychosis

M. Desco, J. Pascau, V. Molina, 2005 .

Background Decreasedmetabolic activity in the prefrontal cortexduring cognitive activation is a recurrent finding and a likely functionalmarkerof

M. Desco, J. Pascau, V. Molina, 2005 .

Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia

M. Desco, J. Pascau, V. Molina, 2005, Schizophrenia Research.

Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin‐1 beta gene (2q13)

J. Sanz, S. Reig, Lourdes Fañanás, 2008, Genes, brain, and behavior.

Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia

M. Desco, J. Pascau, V. Molina, 2003, Psychiatry Research: Neuroimaging.

Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients

L. Fañanás, S. Papiol, V. Molina, 2011, NeuroImage.